No Data
Jiangsu Yahong Meditech Co., Ltd.'s (SHSE:688176) Intrinsic Value Is Potentially 88% Above Its Share Price
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.
On the evening of October 29, YAHONG PHARMACEUTICAL (688176.SH) disclosed its third quarter report. The company achieved revenue of 58.4582 million yuan in the third quarter, a year-on-year increase of 1903.16%; for the first three quarters, the cumulative revenue was 0.139 billion yuan, a year-on-year increase of 4537.79%. The revenue growth is mainly attributed to the company starting to sell its drug Pipatinib Tablets (brand name: Dipatte) and Nilotinib Maleate Tablets (brand name: Ouyoubi) in the fourth quarter of 2023. Commercial promotion has steadily progressed during this reporting period, leading to an increase in sales volume.
Yahong Pharmaceutical (688176.SH): The clinical trial application for APL-2302 has been approved by the FDA.
YAHONG Pharmaceuticals (688176.SH) announced that the company has received a notice from the Food and Drug Administration (referred to as the “FDA…
Yaohong Pharmaceuticals (688176.SH): has repurchased 1.4651% of the shares accumulated.
On October 8, Gronghui reported that as of September 30, 2024, YAHONG Pharmaceuticals (688176.SH) has cumulatively repurchased 8,351,322 shares, accounting for 1.4651% of the total share capital. The highest price for repurchase transactions is RMB 6.73 per share, the lowest price is RMB 4.99 per share, and the total funds paid amount to RMB 47.787 million (excluding stamp duty, transaction commissions and other transaction costs).
Jiangsu Yahong Meditech Finishes Phase 2 Trial for Muscle-Invasive Bladder Cancer Pre-Treatment Combo
No Data